Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know

EP: 1.Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms

EP: 2.Comprehensive Patient Education and Symptom Awareness with GVHD

EP: 3.Managing Severe Symptoms and Disease Progression in the GVHD Journey

EP: 4.Early Symptom Detection and the Impact on Patient Outcomes in GVHD

EP: 5.Patient Communication and Collaborative Care for Symptom Management

Now Viewing

EP: 6.Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know

EP: 7.Treatment with Axatilimab in Chronic GVHD: How it Works and Insights into Treatment Efficacy

EP: 8.Looking Ahead: The Future of Chronic GVHD Management and Patient Care

Video content above is prompted by the following:

Let's discuss the current treatment landscape for cGVHD, including emerging therapies and their potential impact on patient care.

• Can you provide an overview of the current treatment approaches for cGVHD? Please highlight GVHD management relies on immunosuppressive treatments like corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Several agents have been approved for various GVHD settings, including axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept.
  • What key things should patients be aware of when receiving therapies?